Identifying fibroblast growth factor receptor genetic alterations using RNA‐based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment

Erdafitinib, a pan‐fibroblast growth factor receptor (FGFR) inhibitor received accelerated approval from the US Food and Drug Administration (FDA) for locally advanced or metastatic urothelial carcinoma (mUC) in adult patients with specific FGFR3/2 genetic alterations who progressed during or after...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Songbai, Burgess, Mike, Major, Christopher, English, Alistair, Sweeney, Maranna, Hartmann, Arndt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339159/
https://www.ncbi.nlm.nih.gov/pubmed/32304281
http://dx.doi.org/10.1002/cjp2.163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339159/
https://www.ncbi.nlm.nih.gov/pubmed/32304281
http://dx.doi.org/10.1002/cjp2.163

Ejemplares similares